Wikipedia

Daptomycin

Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.[4]

Daptomycin
Clinical data
Trade namesCubicin, Cubicin RF, Dapzura RT
Other namesLY 146032
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding90–95%
Elimination half-life7–11 hours (up to 28 hours in renal impairment)
ExcretionKidney (78%; primarily as unchanged drug); faeces (5.7%)
Identifiers
  • N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine[egr]1-lactone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.116.065 Edit this at Wikidata
Chemical and physical data
FormulaC72H101N17O26
Molar mass1620.693 g·mol−1
  • InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 --> ☒N
  • Key:DOAKLVKFURWEDJ-RWDRXURGSA-N checkY
 ☒NcheckY (what is this?)  (verify)
Daptomycin
1. Daptomycin binds and inserts into the cell membrane. 2. It aggregates in the membrane. 3. It alters the shape of the membrane to form a hole, allowing ions in and out of the cell easily.
Identifiers
SymbolN/A
TCDB1.D.15
OPM superfamily163
OPM protein1t5n

Daptomycin was removed from the World Health Organization's List of Essential Medicines in 2019.[7][8] The World Health Organization classifies daptomycin as critically important for human medicine.[9]

Medical uses

edit

In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteraemia, and right-sided S. aureus endocarditis.[4] It binds avidly to pulmonary surfactant, so cannot be used in the treatment of pneumonia.[10] There seems to be a difference in working daptomycin on hematogenous pneumonia.[11]

Adverse effects

edit

Common adverse drug reactions associated with daptomycin therapy include:[4][12]

Less common, but serious adverse events reported in the literature include

Also, myopathy and rhabdomyolysis have been reported in patients simultaneously taking statins,[15] but whether this is due entirely to the statin or whether daptomycin potentiates this effect is unknown. Due to the limited data available, the manufacturer recommends that statins be temporarily discontinued while the patient is receiving daptomycin therapy. Creatine kinase levels are usually checked regularly while individuals undergo daptomycin therapy.[citation needed]

In July 2010, the FDA issued a warning that daptomycin could cause life-threatening eosinophilic pneumonia. The FDA said it had identified seven confirmed cases of eosinophilic pneumonia between 2004 and 2010 and an additional 36 possible cases. The seven confirmed cases were all older than 60 and symptoms appeared within two weeks of initiation of therapy.[citation needed]

Pharmacology

edit

Mechanism of action

edit

Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death.[16]

It has been proposed that the formation of spherical micelles[17] by daptomycin may affect the mode of action.

Microbiology

edit

Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci,[18] corynebacteria and stationary-phase Borrelia burgdorferi persisters.[19]

Daptomycin resistance

edit

Daptomycin resistance is still uncommon,[when?] but has been increasingly reported in GRE, starting in Korea in 2005, in Europe in 2010, in Taiwan 2011, and in the United States, where nine cases have been reported from 2007 to 2011.[20] Daptomycin resistance emerged in five of the six cases while they were treated. The mechanism of resistance is unknown. A four-million year-old strain of Paenibacillus isolated from soil samples in Lechuguilla Cave was found to be naturally resistant to daptomycin.[21]

It has been suggested that co-administration of daptomycin with at least another active antibiotic might help prevent the emergence of resistance and increase the bactericidal effect.[22] Data from in vitro and in vivo studies suggest that a tailored approach should be used taking into account both the causative agent and the site of infection.[23]

Efficacy

edit

Daptomycin has been shown to be non-inferior to standard therapies (nafcillin, oxacillin, flucloxacillin or vancomycin) in the treatment of bacteraemia and right-sided endocarditis caused by S. aureus.[24] A study in Detroit, Michigan compared 53 patients treated for suspected MRSA skin or soft tissue infection with daptomycin against vancomycin, showing faster recovery (4 versus 7 days) with daptomycin.[25]

In Phase III clinical trials, limited data showed daptomycin to be associated with poor outcomes in patients with left-sided endocarditis.[citation needed] Daptomycin has not been studied in patients with prosthetic valve endocarditis or meningitis.[26]

Biosynthesis

edit
 
Figures 1–7. Biosynthesis of daptomycin
 
Figure 8. Structures of lipopeptide antibiotics Colors highlight the positions in daptomycin that have been modified by genetic engineering, as well as the origins of modules or subunits from A54145 or calcium-dependent antibiotic (CDA).[27]
 
Figure 9. Combinatorial biosynthesis of lipopeptide antibiotics related to daptomycin. Position 8, which typically has D-Ala in daptomycin, was modified by module exchanges to contain D-Ser, D-Asn or D-Lys; position 11, which naturally has D-Ser, was modified by module exchanges to consist of D-Ala or D-Asn; position 12, which normally has 3-methyl-L-Glu, was modified by deletion of the methyltransferase gene to possess L-Glu; position 13, which normally has L-kynurenine (L-Kyn), was modified by subunit exchanges to contain L-Trp, L-Ile or L-Val; position 1 usually includes the anteiso-undecanoyl, isododecanoyl and anteiso-tridecanoyl fatty acyl groups. All of these alterations have been combinatorialized. [27]

Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces filamentosus.[28][29] Daptomycin consists of 13 amino acids, 10 of which are arranged in a cyclic fashion, and three on an exocyclic tail. Two nonproteinogenic amino acids exist in the drug, the unusual amino acid L-kynurenine (Kyn), only known to daptomycin, and L-3-methylglutamic acid (mGlu). The N-terminus of the exocyclic tryptophan residue is coupled to decanoic acid, a medium-chain (C10) fatty acid. Biosynthesis is initiated by the coupling of decanoic acid to the N-terminal tryptophan, followed by the coupling of the remaining amino acids by nonribosomal peptide synthetase (NRPS) mechanisms. Finally, a cyclization event occurs, which is catalyzed by a thioesterase enzyme, and subsequent release of the lipopeptide is granted. [citation needed]

The NRPS responsible for the synthesis of daptomycin is encoded by three overlapping genes, dptA, dptBC and dptD. The dptE and dptF genes, immediately upstream of dptA, are likely to be involved in the initiation of daptomycin biosynthesis by coupling decanoic acid to the N-terminal Trp.[30] These novel genes (dptE, dptF ) correspond to products that most likely work in conjunction with a unique condensation domain to acylate the first amino acid (tryptophan). These and other novel genes (dptI, dptJ) are believed to be involved in supplying the nonproteinogenic amino acids L-3-methylglutamic acid and Kyn; they are located next to the NRPS genes.[30]

The decanoic acid portion of daptomycin is synthesized by fatty acid synthase machinery (Figure 2). Post-translational modification of the apo-acyl carrier protein (ACP, thiolation, or T domain) by a phosphopantetheinyltransferase (PPTase) enzyme catalyzes the transfer of a flexible phosphopantetheine arm from coenzyme A to a conserved serine in the ACP domain through a phosphodiester linkage. The holo-ACP can provide a thiol on which the substrate and acyl chains are covalently bound during chain elongations. The two core catalytic domains are an acyltransferase (AT) and a ketosynthase (KS). The AT acts upon a malonyl-CoA substrate and transfers an acyl group to the thiol of the ACP domain. This net transthiolation is an energy-neutral step. Next, the acyl-S-ACP gets transthiolated to a conserved cysteine on the KS; the KS decarboxylates the downstream malonyl-S-ACP and forms a β-ketoacyl-S-ACP. This serves as the substrate for the next cycle of elongation. Before the next cycle begins, however, the β-keto group undergoes reduction to the corresponding alcohol catalyzed by a ketoreductase domain, followed by dehydration to the olefin catalyzed by a dehydratase domain, and finally reduction to the methylene catalyzed by an enoylreductase domain. Each KS catalytic cycle results in the net addition of two carbons. After three more iterations of elongation, a thioesterase enzyme catalyzes the hydrolysis, and thus release, of the free C-10 fatty acid.[medical citation needed]

To synthesize the peptide portion of daptomycin, the mechanism of an NRPS is employed. The biosynthetic machinery of an NRPS system is composed of multimodular enzymatic assembly lines that contain one module for each amino acid monomer incorporated.[31] Within each module are catalytic domains that carry out the elongation of the growing peptidyl chain. The growing peptide is covalently tethered to a thiolation domain; here it is termed the peptidyl carrier protein, as it carries the growing peptide from one catalytic domain to the next. Again, the apo-T domain must be primed to the holo-T domain by a PPTase, attaching a flexible phosphopantetheine arm to a conserved serine residue. An adenylation domain selects the amino acid monomer to be incorporated and activates the carboxylate with ATP to make the aminoacyl-AMP. Next, the A domain installs an aminoacyl group on the thiolate of the adjacent T domain. The condensation (C) domain catalyzes the peptide bond forming reaction, which elicits chain elongation. It joins an upstream peptidyl-S-T to the downstream aminoacyl-S-T (Figure 7). Chain elongation by one aminoacyl residue and chain translocation to the next T domain occurs in concert. The order of these domains is C-A-T. In some instances, an epimerization domain is necessary in those modules where L-amino acid monomers are to be incorporated and epimerized to D-amino acids. The domain organization in such modules is C-A-T-E.[31]

The first module has a three-domain C-A-T organization; these often occur in assembly lines that make N-acylated peptides.[31] The first C domain catalyzes N-acylation of the initiating amino acid (tryptophan) while it is installed on T. An adenylating enzyme (Ad) catalyzes the condensation of decanoic acid and the N-terminal tryptophan, which incorporates decanoic acid into the growing peptide (Figure 3). The genes responsible for this coupling event are dptE and dptF, which are located upstream of dptA, the first gene of the Daptomycin NRPS biosynthetic gene cluster. Once the coupling of decanoic acid to the N-terminal tryptophan residue occurs, the condensation of amino acids begins, catalyzed by the NRPS.[medical citation needed]

The first five modules of the NRPS are encoded by the dptA gene and catalyze the condensation of L-tryptophan, D-asparagine, L-aspartate, L-threonine, and glycine, respectively (Figure 4). Modules 6–11, which catalyze the condensation of L-ornithine, L-aspartate, D-alanine, L-aspartate, glycine, and D-serine are encoded for the dptBC gene (Figure 5). dptD catalyzes the incorporation of two nonproteinogenic amino acids, L-3-methylglutamic acid (mGlu) and Kyn, which is only known thus far to daptomycin, into the growing peptide (Figure 6).[29] Elongation by these NRPS modules ultimately leads to macrocyclization and release in which an α-amino group, namely threonine, acts as an internal nucleophile during cyclization to yield the 10-amino-acid ring (Figure 6). The termination module in the NRPS assembly line has a C-A-T-TE organization. The thioesterase domain catalyzes chain termination and release of the mature lipopeptide.[31]

The molecular engineering of daptomycin, the only marketed acidic lipopeptide antibiotic to date (Figure 8), has seen many advances since its inception into clinical medicine in 2003.[32] It is an attractive target for combinatorial biosynthesis for many reasons: second generation derivatives are currently in the clinic for development;[33] Streptomyces roseosporus, the producer organism of daptomycin, is amenable to genetic manipulation;[34] the daptomycin biosynthetic gene cluster has been cloned, sequenced, and expressed in S. lividans;[33] the lipopeptide biosynthetic machinery has the potential to be interrupted by variations of natural precursors, as well as precursor-directed biosynthesis, gene deletion, genetic exchange, and module exchange;[34] the molecular engineering tools have been developed to facilitate the expression of the three individual NRPS genes from three different sites in the chromosome, using ermEp* for expression of two genes from ectopic loci;[35] other lipopeptide gene clusters, both related and unrelated to daptomycin, have been cloned and sequenced,[27] thus providing genes and modules to allow the generation of hybrid molecules;[34] derivatives can be afforded via chemoenzymatic synthesis;[36] and lastly, efforts in medicinal chemistry are able to further modify these products of molecular engineering.[33]

New derivatives of daptomycin (Figure 9) were originally generated by exchanging the third NRPS subunit (dptD) with the terminal subunits from the A54145 (Factor B1) or calcium-dependent antibiotic pathways to create molecules containing Trp13, Ile13, or Val13.[37] dptD is responsible for incorporating the penultimate amino acid, 3-methyl-glutamic acid (3mGlu12), and the last amino acid, Kyn13, into the chain. This exchange was achieved without engineering the interpeptide docking sites. These whole-subunit exchanges have been coupled with the deletion of the Glu12-methyltransferase gene, with module exchanges at intradomain linker sites at Ala8 and Ser11, and with variations of natural fatty-acid side chains to generate over 70 novel lipopeptides in significant quantities; most of these resultant lipopeptides have potent antibacterial activities.[27][37] Some of these compounds have in vitro antibacterial activities analogous to daptomycin. Further, one displayed ameliorated activity against an E. coli imp mutant that was defective in its ability to assemble its inherent lipopolysaccharide. A number of these compounds were produced in yields that spanned from 100 to 250 mg/liter; this, of course, opens up the possibility for successful scale-ups by fermentation techniques. Only a small percentage of the possible combinations of amino acids within the peptide core have been investigated thus far.[38]

History

edit

Daptomycin, originally designated as LY 146032, was discovered by researchers at Eli Lilly and Company in the late 1980s from the actinomycete Streptomyces roseosporus. LY 146032 showed promise in phase I/II clinical trials for treatment of infection caused by Gram-positive organisms. Lilly ceased development because high-dose therapy was associated with adverse effects on skeletal muscle, including myalgia.[39][40]

The rights to LY 146032 were acquired by Cubist Pharmaceuticals in 1997, which following U.S. Food and Drug Administration (FDA) approval in September 2003, for use in people older than 18 years, began marketing the drug under the trade name Cubicin. Cubicin is marketed in the EU and in several other countries by Novartis following its purchase of Chiron Corporation, the previous licensee.[40][41]

References

edit
  1. ^ "Daptomycin Use During Pregnancy". Drugs.com. 3 December 2019. Retrieved 28 August 2020.
  2. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  3. ^ "Cubicin 350 mg powder for solution for injection or infusion - Summary of Product Characteristics (SmPC)". (emc). 24 August 2018. Retrieved 28 August 2020.
  4. ^ a b c d "Cubicin- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Retrieved 28 August 2020.
  5. ^ "Cubicin RF- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Retrieved 28 August 2020.
  6. ^ "Cubicin". European Medicines Agency. 17 September 2018. Retrieved 28 August 2020.
  7. ^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
  8. ^ World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
  9. ^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.
  10. ^ Baltz RH (April 2009). "Daptomycin: mechanisms of action and resistance, and biosynthetic engineering". Current Opinion in Chemical Biology. 13 (2): 144–151. doi:10.1016/j.cbpa.2009.02.031. PMID 19303806.
  11. ^ Henken S, Bohling J, Martens-Lobenhoffer J, Paton JC, Ogunniyi AD, Briles DE, et al. (February 2010). "Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae". Antimicrobial Agents and Chemotherapy. 54 (2): 707–717. doi:10.1128/AAC.00943-09. PMC 2812129. PMID 19917756.
  12. ^ Klasco RK, ed. (2006). "Daptomycin". Drugdex System. Vol. 129.
  13. ^ Mo Y, Nehring F, Jung AH, Housman ST (June 2016). "Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review". Journal of Pharmacy Practice. 29 (3): 253–256. doi:10.1177/0897190015625403. PMID 26763341. S2CID 26176155.
  14. ^ Kazory A, Dibadj K, Weiner ID (March 2006). "Rhabdomyolysis and acute renal failure in a patient treated with daptomycin". The Journal of Antimicrobial Chemotherapy. 57 (3): 578–579. doi:10.1093/jac/dki476. PMID 16410267.
  15. ^ Odero RO, Cleveland KO, Gelfand MS (June 2009). "Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor". The Journal of Antimicrobial Chemotherapy. 63 (6): 1299–1300. doi:10.1093/jac/dkp127. PMID 19346518.
  16. ^ Pogliano J, Pogliano N, Silverman JA (September 2012). "Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins". Journal of Bacteriology. 194 (17): 4494–4504. doi:10.1128/JB.00011-12. PMC 3415520. PMID 22661688.
  17. ^ Kirkham S, Castelletto V, Hamley IW, Inoue K, Rambo R, Reza M, Ruokolainen J (July 2016). "Self-Assembly of the Cyclic Lipopeptide Daptomycin: Spherical Micelle Formation Does Not Depend on the Presence of Calcium Chloride" (PDF). ChemPhysChem. 17 (14): 2118–2122. doi:10.1002/cphc.201600308. PMID 27043447. S2CID 44681934.
  18. ^ Shoemaker DM, Simou J, Roland WE (June 2006). "A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections". Therapeutics and Clinical Risk Management. 2 (2): 169–174. doi:10.2147/tcrm.2006.2.2.169. PMC 1661656. PMID 18360590.
  19. ^ Feng J, Weitner M, Shi W, Zhang S, Zhang Y (2016). "Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime". Frontiers in Microbiology. 7: 62. doi:10.3389/fmicb.2016.00062. PMC 4748043. PMID 26903956.
  20. ^ Cleveland KO, Gelfand MS (May 2013). "Daptomycin-Nonsusceptible Enterococcal Infections". Infectious Diseases in Clinical Practice. 21 (3): 213. doi:10.1097/IPC.0b013e31828875fc.
  21. ^ Pawlowski AC, Wang W, Koteva K, Barton HA, McArthur AG, Wright GD (December 2016). "A diverse intrinsic antibiotic resistome from a cave bacterium". Nature Communications. 7: 13803. Bibcode:2016NatCo...713803P. doi:10.1038/ncomms13803. PMC 5155152. PMID 27929110.
  22. ^ Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. (November 2015). "2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)". European Heart Journal. 36 (44): 3075–3128. doi:10.1093/eurheartj/ehv319. PMID 26320109.
  23. ^ Antonello RM, Canetti D, Riccardi N (December 2022). "Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review". The Journal of Antimicrobial Chemotherapy. 78 (1): 52–77. doi:10.1093/jac/dkac346. PMID 36227704.
  24. ^ Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. (August 2006). "Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus". The New England Journal of Medicine. 355 (7): 653–665. doi:10.1056/NEJMoa053783. PMID 16914701.
  25. ^ Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, Rybak MJ (December 2007). "Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes". Pharmacotherapy. 27 (12): 1611–1618. doi:10.1592/phco.27.12.1611. PMID 18041881. S2CID 30964162.
  26. ^ "Cubicin (daptomycin for injection)". Cubist Pharmaceuticals. Archived from the original on 11 April 2021. Retrieved 17 March 2018.
  27. ^ a b c d Nguyen KT, Kau D, Gu JQ, Brian P, Wrigley SK, Baltz RH, Miao V (September 2006). "A glutamic acid 3-methyltransferase encoded by an accessory gene locus important for daptomycin biosynthesis in Streptomyces roseosporus". Molecular Microbiology. 61 (5): 1294–1307. doi:10.1111/j.1365-2958.2006.05305.x. PMID 16879412. S2CID 19766889.
  28. ^ Miao V, Coëffet-LeGal MF, Brian P, Brost R, Penn J, Whiting A, et al. (May 2005). "Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry". Microbiology. 151 (Pt 5): 1507–1523. doi:10.1099/mic.0.27757-0. PMID 15870461.
  29. ^ a b Steenbergen JN, Alder J, Thorne GM, Tally FP (March 2005). "Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections". The Journal of Antimicrobial Chemotherapy. 55 (3): 283–288. doi:10.1093/jac/dkh546. PMID 15705644.
  30. ^ a b Mchenney MA, Hosted TJ, Dehoff BS, Rosteck PR, Baltz RH (January 1998). "Molecular cloning and physical mapping of the daptomycin gene cluster from Streptomyces roseosporus". Journal of Bacteriology. 180 (1): 143–151. doi:10.1128/JB.180.1.143-151.1998. PMC 106860. PMID 9422604.
  31. ^ a b c d Fischbach MA, Walsh CT (August 2006). "Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms". Chemical Reviews. 106 (8): 3468–3496. doi:10.1021/cr0503097. PMID 16895337.
  32. ^ Baltz RH (February 1998). "Genetic manipulation of antibiotic-producing Streptomyces". Trends in Microbiology. 6 (2): 76–83. doi:10.1016/S0966-842X(97)01161-X. PMID 9507643.
  33. ^ a b c Baltz RH, Miao V, Wrigley SK (December 2005). "Natural products to drugs: daptomycin and related lipopeptide antibiotics". Natural Product Reports. 22 (6): 717–741. doi:10.1039/b416648p. PMID 16311632.
  34. ^ a b c Baltz RH, Brian P, Miao V, Wrigley SK (February 2006). "Combinatorial biosynthesis of lipopeptide antibiotics in Streptomyces roseosporus". Journal of Industrial Microbiology & Biotechnology. 33 (2): 66–74. doi:10.1007/s10295-005-0030-y. PMID 16193281. S2CID 10856890.
  35. ^ Nguyen KT, Ritz D, Gu JQ, Alexander D, Chu M, Miao V, et al. (November 2006). "Combinatorial biosynthesis of novel antibiotics related to daptomycin". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17462–17467. Bibcode:2006PNAS..10317462N. doi:10.1073/pnas.0608589103. PMC 1859951. PMID 17090667.
  36. ^ Kopp F, Grünewald J, Mahlert C, Marahiel MA (September 2006). "Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure-activity relationship of daptomycin and A54145". Biochemistry. 45 (35): 10474–10481. doi:10.1021/bi0609422. PMID 16939199.
  37. ^ a b Miao V, Coëffet-Le Gal MF, Nguyen K, Brian P, Penn J, Whiting A, et al. (March 2006). "Genetic engineering in Streptomyces roseosporus to produce hybrid lipopeptide antibiotics". Chemistry & Biology. 13 (3): 269–276. doi:10.1016/j.chembiol.2005.12.012. PMID 16638532.
  38. ^ Baltz RH (December 2006). "Molecular engineering approaches to peptide, polyketide and other antibiotics". Nature Biotechnology. 24 (12): 1533–1540. doi:10.1038/nbt1265. PMID 17160059. S2CID 30003086.
  39. ^ Eisenstein BI, Oleson FB, Baltz RH (January 2010). "Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD". Clinical Infectious Diseases. 50 (Supplement_1) (published 1 February 2010): S10–S15. doi:10.1086/647938. PMID 20067387.
  40. ^ a b Tally FP, DeBruin MF (October 2000). "Development of daptomycin for gram-positive infections". The Journal of Antimicrobial Chemotherapy. 46 (4): 523–526. doi:10.1093/jac/46.4.523. PMID 11020247.
  41. ^ Charles PG, Grayson ML (November 2004). "The dearth of new antibiotic development: why we should be worried and what we can do about it". The Medical Journal of Australia. 181 (10): 549–553. doi:10.5694/j.1326-5377.2004.tb06444.x. PMID 15540967. S2CID 18526863.

Further reading

edit
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Daptomycin&oldid=1253076914"